Bullish indicating open at $55-$60, IPO prices at $37
GSK plc (LSE/NYSE:GSK) announced Monday the completion of its acquisition of efimosfermin alfa from Boston Pharmaceuticals. The deal includes an upfront payment of $1.2 billion and up to $800 million in milestone payments, totaling up to $2 billion. GSK will also assume responsibility for additional milestone payments and tiered royalties to Novartis (SIX:NOVN) Pharma AG related to efimosfermin.
Efimosfermin is described as a phase III-ready, investigational specialty medicine intended for the treatment and prevention of progression of steatotic liver disease (SLD), including metabolic dysfunction-associated steatohepatitis (MASH) and alcohol-related liver disease (ALD). The medicine is a once-monthly subcutaneous injection of a fibroblast growth factor 21 (FGF21) analog, currently in clinical development for moderate to advanced fibrosis, including cirrhosis. According to the statement, MASH and ALD are leading causes of liver transplant in the United States.
GSK acquired BP (NYSE:BP) Asset IX, Inc., a subsidiary of Boston Pharmaceuticals, to obtain efimosfermin. The company noted that efimosfermin is not yet approved for use in any country.
Kaivan Khavandi, Senior Vice President and Global Head of Respiratory, Immunology and Inflammation R&D at GSK, stated, “The close of our acquisition for efimosfermin alfa represents a significant expansion of our hepatology pipeline aimed at addressing steatotic and viral drivers of liver disease. Efimosfermin is a key growth opportunity for GSK with multiple development options and potential first launch in 2029.”
GSK indicated that the addition of efimosfermin expands its pipeline for fibro-inflammatory diseases across liver, lung, and kidney. The company is also developing GSK’990, a siRNA therapeutic for other subsets of patients with SLD.
This article is based on a statement from a press release filed with the SEC.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.